Product Details
Product Name:
Polatuzumab |
CAS No.:
2279068-37-8 |
Purity:
99.7% (SEC-HPLC) |
Supply Ability:
10g |
Release date:
2024/11/15 |
Product Introduction
Bioactivity
名稱 | Polatuzumab |
描述 | Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.Polatuzumab can be used to synthesize the antibody-compound coupling, Polatuzumab Vedotin. |
存儲條件 | store at low temperature | store at -20°C | Shipping with blue ice. |
相關產(chǎn)品 | Belantamab | Naratuximab | Trastuzumab | Daratumumab | Datopotamab | Enfortumab | Inebilizumab | Lonigutamab | Sacituzumab | lorvotuzumab | Disitamab | Glembatumumab |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:2285330-15-4
$1860.00 / 100mg
-
CAS:1553-56-6
$63.00 / 25mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$3570.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |